Sign in

Trial result ·

OnabotulinumtoxinA for Painful Foot Dystonia in Parkinson Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.

Written based on 1 research study on PubMed, searched on 3 Nov 2026.

What was studied

This trial tested onabotulinumtoxinA (BTXA) for painful foot dystonia in Parkinson disease (PD). The pain often occurs during OFF periods. It is hard to treat by changing medicine. Evidence on treatment is limited. It was a single-center, randomized, double-blind, placebo-controlled trial. Adults were randomized 1:1 to BTXA (100 units) or placebo. The main outcome was change in dystonia-related pain. It was scored on the King's Parkinson's Disease Pain Scale (KPPS). Outcomes were checked at 6 and 12 weeks.

What they found

16 people got BTXA and 17 got placebo. Pain fell significantly more with BTXA at 6 weeks. The mean difference was -3.60. The effect held at 12 weeks (p < 0.001). The effect size was large (Hedges g -1.33; range -2.13 to -0.53). Pain severity and frequency also improved. VAS pain fell at 6 weeks, with no significant gap at 12 weeks. Responder rates were higher with BTXA at 6 and 12 weeks. Motor outcomes, quality of life and adverse events did not differ. Adverse events were mild.

What it means for patients

The team says BTXA cut foot dystonia pain in PD without harming motor outcomes. They say it was well tolerated. They say this supports its use as a targeted treatment.

Why it is not certain yet

It was a single-center trial. The groups were small, with 16 and 17 people. VAS pain did not differ significantly at 12 weeks. Only adults with PD on one side took part.

Source

OnabotulinumtoxinA for Painful Foot Dystonia in Parkinson Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.

PubMed · PMID 42753227

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Parkinson disease publications